Pfizer Limited reported its latest quarterly financial results, revealing a mixed performance with revenue growth offset by a decline in net profit on a year-on-year basis. The Board of Directors meeting, held on May 12, 2026, also approved the audited financial results for the year ended March 31, 2026, alongside the declaration of a final dividend.

Q4 Financial Performance

Pfizer's Q4 revenue came in at Rs. 6.3 billion, up from Rs. 5.92 billion in the same period last year, reflecting steady top-line growth. However, net profit for the quarter declined to Rs. 2 billion compared to Rs. 3.31 billion in the corresponding period of the previous year. EBITDA for the quarter stood at Rs. 2.36 billion versus Rs. 2.28 billion year-on-year, though the EBITDA margin contracted slightly to 37.46% from 38.40% in the year-ago period.

The key quarterly financial metrics are summarised below:

Final Dividend Declared

The Board has recommended a final dividend of Rs. 75 per equity share of Rs. 10 each, amounting to 750%, for the financial year ended March 31, 2026. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has fixed Friday, July 17, 2026, as the record date to determine the entitlement of members to the final dividend. The payment is scheduled to be made on or after August 4, 2026, subject to shareholder approval at the ensuing Annual General Meeting.

The key dividend details are summarised below:

The Board meeting commenced at 1.30 p.m. and concluded at 6.30 p.m. The company operates solely in the Pharmaceuticals segment and confirmed that it does not fall under the category of a Large Corporate as at March 31, 2026.

Pfizer Limited has informed stock exchanges of the appointment of M/s. Kishore Bhatia & Associates as its Cost Auditors for the financial year ending March 31, 2027. The decision was taken by the Board of Directors, acting on the recommendation of the Audit Committee, at their meeting held on May 12, 2026. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

The key details of the appointment, as disclosed in Annexure A filed with the exchanges, are summarised below:

The remuneration payable to M/s. Kishore Bhatia & Associates shall be placed before the shareholders for ratification at the ensuing Annual General Meeting.

Profile of the Appointed Firm

M/s. Kishore Bhatia & Associates is a firm of Practicing Cost Accountants based in Mumbai, offering a wide spectrum of services to its clientele. The firm has handled various assignments in costing, including:

• Cost audits and certifications
• Setting up costing systems
• Cost consultancy
• Costing-based turnaround strategies
• Internal audit, stock and assets verification, and industry studies

The firm has conducted Cost Audits for clients across diverse industries, including Pharmaceuticals, Engineering, Chemicals, Insecticides, Construction, Real Estate, Steel, Infrastructure, Telecommunications, Plastics & Polymers, Petroleum, FMCG, Medical Devices, Ports, Roads, Paints, and Energy. The firm comprises highly qualified Partners supported by an experienced professional team.

Regulatory Compliance

The filing was made in accordance with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The disclosure was signed by Prajeet Nair, Director – Corporate Services & Company Secretary of Pfizer Limited, on May 12, 2026.